<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">279906</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Trudnyy patsient: obostreniya khronicheskoy obstruktivnoy bolezni legkikh tyazhelogo techeniya</article-title><trans-title-group xml:lang="ru"><trans-title>Трудный пациент: обострения хронической обструктивной болезни легких тяжелого течения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nonikov</surname><given-names>V. E</given-names></name><name xml:lang="ru"><surname>Ноников</surname><given-names>В. Е</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mozzhukhina</surname><given-names>E. V</given-names></name><name xml:lang="ru"><surname>Мозжухина</surname><given-names>Е. В</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н.</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ЦКБ УД Президента РФ</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2012</year></pub-date><volume>19</volume><issue>15</issue><issue-title xml:lang="en">NO15 (2012)</issue-title><issue-title xml:lang="ru">№15 (2012)</issue-title><fpage>81</fpage><lpage>83</lpage><history><date date-type="received" iso-8601-date="2023-02-24"><day>24</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, ООО «Бионика Медиа»</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/279906">https://journals.eco-vector.com/2073-4034/article/view/279906</self-uri><abstract xml:lang="en"><p>The article considers the main recommendations for the treatment of chronic obstructive pulmonary disease (COPD), especially severe forms. In particular, the features of broncholytic and antibacterial therapy for severe exacerbation of COPD are discussed. Successful treatment of COPD exacerbations reduces the risk of a fatal outcome. In the case of use of systematic drug therapy, prevention of exacerbation and rehabilitation activities, prognosis of future course of the disease could be better.</p></abstract><trans-abstract xml:lang="ru"><p>Рассматриваются основные рекомендации по лечению хронической обструктивной болезни легких (ХОБЛ), прежде всего тяжелых его форм. В частности, обсуждаются особенности бронходилатирующей и антибиотикотерапии при критически тяжелых обострениях ХОБЛ. Успешное лечение обострений ХОБЛ уменьшает риск фатального исхода. Прогноз дальнейшего течения заболевания улучшается, если проводится систематическая медикаментозная терапия, используются методы профилактики обострений и реабилитационные мероприятия.</p></trans-abstract><kwd-group xml:lang="en"><kwd>chronic obstructive pulmonary disease</kwd><kwd>respiratory failure</kwd><kwd>broncholytic therapy</kwd><kwd>antibacterial treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая обструктивная болезнь легких</kwd><kwd>легочная недостаточность</kwd><kwd>бронхолитическая терапия</kwd><kwd>антибиотикотерапия</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Global Initiative for Chronic Obstructive Lung Diseases (NHLB/WHO Workshop Report), National Institutes of Health. 2009:90.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Ноников В.Е. Хроническая обструктивная болезнь легких. В кн.: Основы клинической гериатрии. Практическое руководство / Под ред. С.П. Миронова и АТ. Арутюнова. М., 2008. 512 с.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Dahl R, Greefhorst L, Novak D, et al. Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001;164(5):778-84.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Casaburi R, Mahler D, Jones P, et al. A long term evaluation of once-daily inhaled tiotropium in Chronic obstructive pulmonary disease. Eur Respir J 2002;19(2):212-24.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with COPD: a mechanism for increased cardiovascular risk Thorax 2008;63(4):206-11.</mixed-citation></ref></ref-list></back></article>
